genprowebdirectory
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Insights
Trends for 2020
Trends for 2021
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Magazine
Current Issue
Past Issues
Supplements
Subscribe
GEN Protocols
Resources
Summits
Webinars
GEN Live
eBooks/Perspectives
Podcasts
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
– INSIDE –
PRECISION MEDICINE
Search
About GEN
Contact GEN
Subscribe/Update Preferences
Log In
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Create an account
Privacy Policy
Create an account
Welcome! Register for an account
your email
your username
A password will be e-mailed to you.
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Bioprocessing
Lonza Plans New Fill & Finish Facility in Stein, Switzerland
Bioprocessing
Harnessing Bacteria to Make Jet Fuel: Not Just An “Explosive Idea?”
Drug Discovery
Potential Therapeutic Treatment for Androgenetic Alopecia
Dengue
Mosquitoes Find Humans Infected with Zika or Dengue Viruses More Attractive
Infectious Diseases
Enteric Viruses Shown Capable of Spreading via Saliva
Insights
All
Trends for 2020
Trends for 2021
Insights
Single-Cell Functional Proteome Profiling Uncovers Novel Targets for Alzheimer’s Disease
Artificial Intelligence
AI Can Make a Difference on the Factory Floor If Biopharma…
Bioprocessing
Separation Technique Adjusted for mRNA Vaccine Boom
Antibodies
Combatting Therapeutic-Protein Aggregation
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
A-Lists
Top 10 Spatial Biology Companies
A-Lists
Top 25 Biotech Companies of 2022
A-Lists
Seven Biopharma Trends to Watch in 2022
A-Lists
Six of the Best Reports from the Front Line of Biotechnology
A-Lists
Top 10 RNA-Based Biopharmas
Magazine
Current Issue
Past Issues
Supplements
Subscribe
GEN Protocols
Resources
Summits
Webinars
GEN Live
eBooks/Perspectives
Podcasts
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
– INSIDE –
PRECISION MEDICINE
Home
Neurological Disorders
ALS
ALS
ALS
Alzheimers
Mental Health Disorders
Parkinsons
Schizophrenia
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Financing
StockWatch: Layoffs Fail to Lift Novartis
ALS
Triple Threat: NeuroSense Targets ALS
Neurological Disorders
StockWatch: Praxis Shares Crater 75% as Aria Strikes a Sour Note
Neurological Disorders
StockWatch: ALS Setback Hammers Amylyx, Longeveron Doubles on Positive Alzheimer’s Data
ALS
ALS-Linked TDP-43 Aggregates Seen Clearly Enough to Raise Treatment Hopes
ALS
Steering Stem Cells to Repair Sites Using Inflammo-Free Inflammo-Attraction
Sponsored
Working with ALS Mice: Guidelines for Preclinical Testing and Colony Management
ALS
Neurodegenerative Treatments Build to a Tipping Point
ALS
Is ALS More Genetically Driven than Once Thought?
ALS
Sanofi, Denali Launch $1B+ Alliance to Develop RIPK1 Inhibitors for Neurological,...
ALS
Amyloids Shown to Also Play Beneficial Role in Developing Healthy Muscle...
ALS
Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders
ALS
Flex Pharma Axes 60% of Workforce, Explores Sale after Halting Phase...
ALS
Neuraltus Weighs Future of Lead Candidate NP001 after Failure in Phase...
ALS
Biogen, Ionis Launch $1B+ Expanded Neuro Drug Partnership, following Spinraza Success
1
2
3
Page 1 of 3
Scroll Up
![Flex Pharma cites unspecified “oral tolerability concerns” in halting Phase II trials of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT). [© whitehoune / Fotolia]](https://www.genengnews.com/wp-content/uploads/2018/08/170123090806_1_900x6009916143062-324x160.jpg "Flex Pharma Axes 60% of Workforce, Explores Sale after Halting Phase II Trials in ALS, CMT")
